Steatosis induced by the accumulation of apolipoprotein A-I and elevated ROS levels in H-ras12V transgenic mice contributes to hepatic lesions

Biochemical and Biophysical Research Communications

Volumn 409, Issue 3, 2011, Pages 532-538

  Wang, Ai Guo ^a   Moon, Hyung Bae ^b   Chae, Jung Il ^c   Kim, Jin Man ^d   Kim, Ye Eun ^f   Yu, Dae Yeul ^e   Lee, Dong Seok ^f  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Wonkwang University   (South Korea)

^c Chonbuk National University   (South Korea)

^d Chungnam National University   (South Korea)

^e Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^f Kyungpook National University   (South Korea)

Author keywords

Apolipoprotein A I; H ras12V; Hepatic lesions; Steatosis; Transgenic mice

Indexed keywords

APOLIPOPROTEIN A1; H RAS12V PROTEIN; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; FATTY LIVER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; LIVER ADENOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER INJURY; LIVER NODULE; MALE; MOUSE; NONHUMAN; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TRANSGENIC ANIMAL;

ANIMALS; APOLIPOPROTEIN A-I; FATTY LIVER; FEMALE; GENES, RAS; LIVER NEOPLASMS; MALE; MICE; MICE, TRANSGENIC; REACTIVE OXYGEN SPECIES;

MUS MUSCULUS;

EID: 79958231017     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.05.039     Document Type: Article

References (31)

1. El-Serag H.B., Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007, 132:2557-2576.
2. Page J.M., Harrison S.A. NASH and HCC. Clin. Liver Dis. 2009, 13:631-647.
3. Marrero J.A., Fontana R.J., Su G.L., Conjeevaram H.S., Emick D.M., Lok A.S. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002, 36:1349-1354.
4. Clouston A.D., Powell E.E. Nonalcoholic fatty liver disease: is all the fat bad?. Intern. Med. J. 2004, 34:187-191.
5. Kurosaki M., Hosokawa T., Matsunaga K., Hirayama I., Tanaka T., Sato M., Yasui Y., Tamaki N., Ueda K., Tsuchiya K., Kuzuya T., Nakanishi H., Itakura J., Takahashi Y., Asahina Y., Enomoto N., Izumi N. Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. Hepatol. Res. 2010, 40:870-877.
6. Vigil D., Cherfils J., Rossman K.L., Der C.J. Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?. Nat. Rev. Cancer 2010, 10:842-857.
7. Wu R.F., Terada L.S. Ras and Nox: linked signaling networks?. Free Radic. Biol. Med. 2009, 47:1276-1281.
8. Gotzmann J., Huber H., Thallinger C., Wolschek M., Jansen B., Schulte-Hermann R., Beug H., Mikulits W. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J. Cell Sci. 2002, 115:1189-1202.
9. Staib F., Hussain S.P., Hofseth L.J., Wang X.W., Harris C.C. TP53 and liver carcinogenesis. Hum. Mutat. 2003, 21:201-216.
10. Hopewell S., Pandey N.R., Misquith A., Twomey E., Sparks D.L. Phosphatidylinositol acts through mitogen-activated protein kinase to stimulate hepatic apolipoprotein A-I secretion. Metabolism 2008, 57:1677-1684.
11. Zheng X.L., Matsubara S., Diao C., Hollenberg M.D., Wong N.C. Epidermal growth factor induction of apolipoprotein A-I is mediated by the Ras-MAP kinase cascade and Sp1. J. Biol. Chem. 2001, 276:13822-13829.
12. Karihtala P., Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007, 115:81-103.
13. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2007, 22(Suppl. 1):S20-S27.
14. Wang A.G., Moon H.B., Lee M.R., Hwang C.Y., Kwon K.S., Yu S.L., Kim Y.S., Kim M., Kim J.M., Kim S.K., Lee T.H., Moon E.Y., Lee D.S., Yu D.Y. Gender-dependent hepatic alterations in H-ras12V transgenic mice. J. Hepatol. 2005, 43:836-844.
15. Molloy M.P., Herbert B.R., Walsh B.J., Tyler M.I., Traini M., Sanchez J.C., Hochstrasser D.F., Williams K.L., Gooley A.A. Extraction of membrane proteins by differential solubilization for separation using two-dimensional gel electrophoresis. Electrophoresis 1998, 19:837-844.
16. Kim S.K., Yoo J.I., Cho B.K., Hong S.J., Kim Y.K., Moon J.A., Kim J.H., Chung Y.N., Wang K.C. Elevation of CRABP-I in the cerebrospinal fluid of patients with Moyamoya disease. Stroke 2003, 34:2835-2841.
17. Stoehr S.A., Isom H.C. Gap junction-mediated intercellular communication in a long-term primary mouse hepatocyte culture system. Hepatology 2003, 38:1125-1135.
18. Frith C.H., Ward J.M. A morphologic classification of proliferative and neoplastic hepatic lesions in mice. J. Environ. Pathol. Toxicol. 1979, 3:329-351.
19. Yu D.Y., Moon H.B., Son J.K., Jeong S., Yu S.L., Yoon H., Han Y.M., Lee C.S., Park J.S., Lee C.H., Hyun B.H., Murakami S., Lee K.K. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. Hepatol. 1999, 31:123-132.
20. Kohli R., Pan X., Malladi P., Wainwright M.S., Whitington P.F. Mitochondrial reactive oxygen species signal hepatocyte steatosis by regulating the phosphatidylinositol 3-kinase cell survival pathway. J. Biol. Chem. 2007, 282:21327-21336.
21. Tanaka A., Uegaki S., Kurihara H., Aida K., Mikami M., Nagashima I., Shiga J., Takikawa H. Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J. Gastroenterol. 2007, 13:5180-5187.
22. Kumar D., Farrell G.C., Kench J., George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J. Gastroenterol. Hepatol. 2005, 20:1395-1400.
23. Ohata K., Hamasaki K., Toriyama K., Matsumoto K., Saeki A., Yanagi K., Abiru S., Nakagawa Y., Shigeno M., Miyazoe S., Ichikawa T., Ishikawa H., Nakao K., Eguchi K. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 2003, 97:3036-3043.
24. Zhu A.X., Chung R.T. Hepatic steatosis in patients with chronic hepatitis C virus infection. Another risk factor for hepatocellular carcinoma?. Cancer 2003, 97:2948-2950.
25. Tronstad K.J., Berge K., Berge R.K., Bruserud O. Modified fatty acids and their possible therapeutic targets in malignant diseases. Expert Opin. Ther. Targets 2003, 7:663-677.
26. Wang A.G., Lee D.S., Moon H.B., Kim J.M., Cho K.H., Choi S.H., Ha H.L., Han Y.H., Kim D.G., Hwang S.B., Yu D.Y. Non-structural 5A protein of hepatitis C virus induces a range of liver pathology in transgenic mice. J. Pathol. 2009, 219:253-262.
27. Zhang L., Perdomo G., Kim D.H., Qu S., Ringquist S., Trucco M., Dong H.H. Proteomic analysis of fructose-induced fatty liver in hamsters. Metabolism 2008, 57:1115-1124.
28. Fernandez-Miranda C., Perez-Carreras M., Colina F., Lopez-Alonso G., Vargas C., Solis-Herruzo J.A. A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease. Dig. Liver Dis. 2008, 40:200-205.
29. Lam J.K., Matsubara S., Mihara K., Zheng X.L., Mooradian A.D., Wong N.C. Insulin induction of apolipoprotein AI, role of Sp1. Biochemistry 2003, 42:2680-2690.
30. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
31. Anezaki Y., Ohshima S., Ishii H., Kinoshita N., Dohmen T., Kataoka E., Sato W., Iizuka M., Goto T., Sasaki J., Sasaki T., Suzuki A., Ohnishi H., Horie Y. Sex difference in the liver of hepatocyte-specific Pten-deficient mice. A model of nonalcoholic steatohepatitis. Hepatol. Res. 2009, 39:609-618.